 Brian Law, Ph.D., B.Sc.
Brian Law received a first in chemistry from the University of Newcastle upon Tyne and his PhD in analytical toxicology from the University of Surrey. He worked in the Home Office Forensic Science Service for 15 years in the area of drug analysis and toxicology, both in routine and research laboratories. In 1984 Brian moved to ICI Pharmaceuticals (now AstraZeneca) as a Senior Methods Developer in the Drug Metabolism and Pharmacokinetics (DMPK) section.
Brian has held a number of positions at AstraZeneca where in addition to drug analysis he has lead groups involved with drug formulation, instrument support and physical sciences. In 1996 Brian moved into Drug Discovery to develop and lead the Bioavailability Screening Group which was responsible for the application of high-throughput analytical methods to early drug discovery projects. Following the merger with Astra in 1999, Brian moved back into DMPK where he was the Associate Director responsible for all the high throughput in vivo and in vitro screening. In June 2003 Brian took a secondment to Computational Chemistry to further develop his data mining and SAR skills. More recently Brian has been involved with business improvement projects in the scientific area employing Lean Sigma techniques.
Brian is a Fellow of the Royal Society of Chemistry and a visiting professor at the University of Sunderland. He has published over 60 research papers, book chapters and books in the areas of radioimmunoassay, chromatography and drug analysis in general.
Brian’s interests include photography, rock climbing, walking and drinking real ale.
 Matthew Stirling, Ph.D., B.Sc.
Matt has nine years industrial experience in development and optimisation of new technologies with special expertise in homogeneous asymmetric organometallic chemistry.
Matt obtained a first class part time degree with a number of outstanding achievements awards before completing an Industrial PhD sponsored by the Royal Commission for the Exhibition of 1851. His project 'Coupled Catalytic Cycles' lead to the patent of a new class of racemisation catalysts known as SCRAM™ catalysts currently being developed by NPIL Pharma. To date Matt has published two papers and co-authored several patents in the area of asymmetric transfer hydrogenation and amine dynamic kinetic resolution.
 Nicholas Powles, Ph.D., B.Sc.
Nick has eleven years experience in applied physical organic chemistry. He started work for Zeneca in 1995 and studied part-time for a degree, after obtaining a first class degree with a number of outstanding achievements awards, he went on to complete an Industrial PhD with Avecia Biotechnology titled A Physical Organic Approach to the Improvement of Oligonucleotide Synthesis
|
Consultants
